New York, January 22, 2014 -- Moody's Investors Service commented that the announcement that Quest Diagnostics Incorporated (Quest) has entered into a definitive agreement to acquire Solstas Lab Partners Group (Solstas) for approximately $570 million is a credit negative. However, the announcement has no immediate impact on the company's Baa2 senior unsecured rating. The rating outlook is stable.
Vollständigen Artikel bei Moodys lesen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.